Literature DB >> 28849340

Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor.

Masahiko Tanigawa1,2, Masamichi Nakayama1, Tomoki Taira3, Satoshi Hattori4, Yutaro Mihara1,2, Reiichiro Kondo1, Hironori Kusano1, Ken Nakamura1, Yushi Abe1, Yusuke Ishida5, Yoshinobu Okabe5, Toru Hisaka2, Koji Okuda2, Kosuke Fujino6, Takaaki Ito6, Akihiko Kawahara3, Yoshiki Naito7,8, Rin Yamaguchi9, Jun Akiba3, Yoshito Akagi2, Hirohisa Yano1.   

Abstract

Insulinoma-associated protein 1 (INSM1) is an important biomarker of Achaete-scute homolog-like 1-driven pathways. For diagnosis of pancreatic neuroendocrine tumors (PanNET), chromogranin A (CGA), synaptophysin (SYP), and neural cell adhesion molecule (NCAM) were also considered as potential biomarkers. However, it is often difficult to diagnose it immunohistochemically. Hence, we examined the expression pattern of INSM1 in pancreatic solid tumors. We detected INSM1, CGA, SYP, and NCAM immunohistochemically, in 27 cases of NET [pure type: 25 cases, mixed adenoneuroendocrine carcinoma (MANEC): 2 cases]. We included 5 cases of solid-pseudopapillary neoplasm (SPN), 7 cases of acinar cell carcinoma (ACC), and 15 cases of pancreatic ductal adenocarcinoma (PDAC) as the control group. Nuclear expression of INSM1 was found in all PanNET pure type cases. However, expression of INSM1 was negative in PDAC, ACC, and SPN in all cases, whereas faint expression was seen in the cytoplasm from SPN. MANEC comprises of two components: neuroendocrine carcinoma and adenocarcinoma components. The NET component was positive for INSM1 expression, whereas the PDAC component does not express INSM1, which aids in distinguishing these components. Our results suggest that INSM1 is a useful immunohistochemical marker for diagnosing pancreatic neuroendocrine tumor.

Entities:  

Keywords:  INSM1; Immunohistochemical marker; Neuroendocrine tumor; Pancreas; Solid-pseudopapillary neoplasm

Mesh:

Substances:

Year:  2017        PMID: 28849340     DOI: 10.1007/s00795-017-0167-6

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  20 in total

1.  Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10.

Authors:  K Notohara; S Hamazaki; C Tsukayama; S Nakamoto; K Kawabata; K Mizobuchi; K Sakamoto; S Okada
Journal:  Am J Surg Pathol       Date:  2000-10       Impact factor: 6.394

2.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

3.  Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis.

Authors:  Zina Meriden; Chanjuan Shi; Barish H Edil; Trevor Ellison; Christopher L Wolfgang; Toby C Cornish; Richard D Schulick; Ralph H Hruban
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

4.  Malignant oncocytic carcinoid of the pancreas.

Authors:  P H Carstens; F K Cressman
Journal:  Ultrastruct Pathol       Date:  1989 Jan-Feb       Impact factor: 1.094

5.  Sex differences in immunohistochemical expression and capillary density in pancreatic solid pseudopapillary neoplasm.

Authors:  Kenichi Hirabayashi; Sachiko Kurokawa; Atsuko Maruno; Misuzu Yamada; Yoshiaki Kawaguchi; Toshio Nakagohri; Tetsuya Mine; Tomoko Sugiyama; Takuma Tajiri; Naoya Nakamura
Journal:  Ann Diagn Pathol       Date:  2015-02-20       Impact factor: 2.090

6.  A novel human insulinoma-associated cDNA, IA-1, encodes a protein with "zinc-finger" DNA-binding motifs.

Authors:  Y Goto; M G De Silva; A Toscani; B S Prabhakar; A L Notkins; M S Lan
Journal:  J Biol Chem       Date:  1992-07-25       Impact factor: 5.157

Review 7.  Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.

Authors:  Daniel M Girardi; Andrea C B Silva; Juliana Florinda M Rêgo; Renata A Coudry; Rachel P Riechelmann
Journal:  Cancer Treat Rev       Date:  2017-04-17       Impact factor: 12.111

Review 8.  Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation.

Authors:  Michael S Lan; Mary B Breslin
Journal:  FASEB J       Date:  2009-02-26       Impact factor: 5.191

9.  TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution.

Authors:  Min Yang; Lin Zeng; Yi Zhang; Wei-Guo Wang; Li Wang; Neng-Wen Ke; Xu-Bao Liu; Bo-le Tian
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

10.  Pancreatic neuroendocrine tumor and solid-pseudopapillary neoplasm: Key immunohistochemical profiles for differential diagnosis.

Authors:  Yusuke Ohara; Tatsuya Oda; Shinji Hashimoto; Yoshimasa Akashi; Ryoichi Miyamoto; Tsuyoshi Enomoto; Kaishi Satomi; Yukio Morishita; Nobuhiro Ohkohchi
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

View more
  14 in total

1.  Insulinoma-associated protein 1(INSM1) is a superior marker for the diagnosis of gastroenteropancreatic neuroendoerine neoplasms: a meta-analysis.

Authors:  Qinghui Zhang; Jiahuang Huang; Yajun He; Runze Cao; Jianchang Shu
Journal:  Endocrine       Date:  2021-05-22       Impact factor: 3.633

Review 2.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

Review 3.  Insulinoma-Associated-1: From Neuroendocrine Tumor Marker to Cancer Therapeutics.

Authors:  Chiachen Chen; Abner L Notkins; Michael S Lan
Journal:  Mol Cancer Res       Date:  2019-05-21       Impact factor: 5.852

4.  INSM1 Expression Is Frequent in Primary Central Nervous System Neoplasms but Not in the Adult Brain Parenchyma.

Authors:  Heather M Ames; Lisa M Rooper; John J Laterra; Charles G Eberhart; Fausto J Rodriguez
Journal:  J Neuropathol Exp Neurol       Date:  2018-05-01       Impact factor: 3.685

5.  A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma.

Authors:  Chiachen Chen; Michael S Lan
Journal:  Cell Signal       Date:  2020-09-20       Impact factor: 4.315

6.  Fibrous Extracellular Spheroids in an Endoscopic Ultrasound-Guided Pancreatic Fine Needle Aspiration Correlating to a Gyriform Pancreatic Endocrine Tumor with a Unique Cobblestone Pavement Growth Pattern.

Authors:  Alessandro Marotta; Jordan P Reynolds; Thomas P Plesec; E Rene Rodriguez; Sunguk N Jang; Maria Luisa C Policarpio-Nicolas; Bridgette Springer; Charles D Sturgis
Journal:  Case Rep Pathol       Date:  2019-10-17

7.  Transcriptomics analysis for the identification of potential age-related genes and cells associated with three major urogenital cancers.

Authors:  Jinlong Cao; Jianpeng Li; Xin Yang; Pan Li; Zhiqiang Yao; Dali Han; Lijun Ying; Lijie Wang; Junqiang Tian
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 8.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

Review 9.  Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic.

Authors:  Alexander Ney; Gabriele Canciani; J Justin Hsuan; Stephen P Pereira
Journal:  Cancers (Basel)       Date:  2020-10-28       Impact factor: 6.639

10.  Mesenchymal/non-epithelial mimickers of neuroendocrine neoplasms with a focus on fusion gene-associated and SWI/SNF-deficient tumors.

Authors:  Atsuko Kasajima; Björn Konukiewitz; Anna Melissa Schlitter; Wilko Weichert; Jan Hinrich Bräsen; Abbas Agaimy; Günter Klöppel
Journal:  Virchows Arch       Date:  2021-08-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.